Cost-effectiveness analysis of the health technologies for treatment of chronic lymphocytic leukemia

Toni Vekov; Slaveyko Djambazov

doi:10.14748/.v2i1.1886

Cost-effectiveness analysis of the health technologies for treatment of chronic lymphocytic leukemia

Toni Vekov, Slaveyko Djambazov

Abstract

Presented are analysis and assessment of target health technologies (antibodies and kinase inhibitors) used to treat chronic lymphocytic leukemia in Bulgaria during 2016. The aim of the study is to create pharmacotherapeutic guidelines for the treatment of CLL, based on clinical data for comparative therapeutic efficacy and economic data for comparative cost-effectiveness of possible therapeutic alternatives (comparators). We perform a systematic review of published data from health technology assessment for the treatment of CLL in MEDLINE, EMBASE, Web of Science, Cochrane Library for the period January 2005-June 2016 data for health benefits in terms of additional QALY, are directly transferred from other countries. Data on the cost of medicines therapies are based on local reference prices in Bulgaria available in the positive drug list to July 2016. The analysis of economic data and health technology assessment in Bulgaria for the treatment of chronic lymphocytic leukemia recommended RIT in combination with FLU and CYC as a possible efficient and cost-effective first-line therapy in patients with CLL and second line therapy in patients with relapsing or refractory CLL. In patients with CLL and deletion 17B or TP53 mutation recommended as first line therapeutic combination therapy both IDE and RIT.

Keywords

chronic lymphocytic leukemia; antibodies; kinase inhibitors; pharmacoeconomic evaluations; therapeutic alternatives; cost-effectiveness

Full Text

References

Ghia P, Hallek M. Haematologica. Management of chronic lymphocytic leukemia.2014 Jun;99(6):965-72.

Михайлов Г, Грудева Ж, Славчева В и др. Хронична лимфоцитна левкемия. Методични насоки за диагностика и лечение на хематологични заболявания. Хематология 51, 2015, 3-4, 100-107.

Заболяемост от рак в България (2012). Български национален раков регистър. Национална болница по онкология. 2014 г.

Salchev P. Objectification of the decision-making in health technology assessment (multi-criteria approach). Bul J Publ Health 8, 2016, 2, 3-30.

Grigorov E,Vaseva V,Getov I, Applied pharmacoeconomics – methodology, structuring and conducting of pharmacoeconomical studies. Journal of International Scientific Publications: Economy & Business 7, 2013,1, 540-551.

Husereau, D, M Drummond, S Petrou, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. BMC Med. 2013; 25(11):80-90.

Позитивен лекарствен списък, юли 2016, www.ncpr.bg

Adena M, Houltram J, Mulligan SP, et al. Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse.Pharmacoeconomics. 2014 Feb;32(2):193-207.

Casado LF, García Marco JA, Gilsanz F, et al.Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia]. Gac Sanit. 2011 Jul-Aug;25(4):274-81.

NICE. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia, 2010.

NICE. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab, 2010.

Xenakis A, Smith N, Beckerman R et al. A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia. 2014 ASCO Annual Meeting, Chicago.

Gouveia M, Silva MG, Alarcão J et al. Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal.Value Health. 2015 Nov;18(7):A461-2.

Marchetti M, Cuneo A, Mauro F et al. Is Idelalisib Cost-Effective for Refractory/Relapsed Chronic Lymphocytic Leukemia? a Decision Analysis in the Second-Line Setting 57th ASH Annual Meeting&Exposition, December 5-8 2015, Orlando, US

Yu JS, Seal B, Carlson JJ. Idelalisib Plus Rituximab Versus Placebo Plus Rituximab For Relapsed Chronic Lymphocytic Leukemia: A Cost-Effectiveness Analysis Value Health 2015 Volume 18, Issue 3, Page A203

Leleu H, Blachier M, Mealing S, et al. Cost-Effectiveness Of Idelalisib Plus Rituximab In Chronic Lymphocytic Leukaemia. Value Health. 2015 Nov;18(7):A460.

Sullivan W, Hadlow S, Perard R et al. The Cost Effectiveness Of Idelalisib In Chronic Lymphocytic Leukaemia In England And Wales. Value Health. 2015 Nov;18(7):A454-5.

NCPE Cost Effectiveness Of Idelalisib (Zydelig) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia: who have received an least of one priore therapy, or as first-line treatment in the presence of 17p deletion/TP53 mutation in patients unsuitable for chemo-immunotherapy. February 2016.

Herring W, Pearson I, Purser M et al. Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90.

Reyes C, Gazauskas G, Becker U et al. Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL). ASH, San Francisco, December, 2014.

Pearson IV, Hawe E, Zuluaga S et al. Cost-Effectiveness Of Ofatumumab Plus Chlorambucil In First-Line Chronic Lymphocytic Leukemia In The United Kingdom. Value Health. 2015 Nov;18(7):A455.

Kumar G, Morton TD, Padhiar A, et al. A Scotland based cost-effectiveness analysis of idelalisib (Zydelig®) in combination with rituximab for the treatment of adults with chronic lymphocytic leukaemia Cll). Value Health. 2015 Nov;18(7):A455.

NCPE. Cost effectiveness of obinutuzumab (Gazyvaro®) (in combination with chlorambucil) for the treatment of adult patients with previously untreated chronic lymphoytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy, April 2015

Paquete A, Miguel LS, Pereira C, Pinto CG. Cost-Effectiveness Analysis Of Obinutuzumab For Previously Untreated Chronic Lymphocytic Leukemia (Cll) In Portuguese Patients That Are Unsuitable For Full-Dose Fludarabine Based Therapy. Value Health. 2015 Nov;18(7):A463-4.

Yagudina R, Kulikov A, Babiy VV. Cost-Effectiveness Analysis Of Obinutuzumab/Chlorambucil Vs Rituximab/Chlorambucil In Treatment Of Chronic Lymphocytic Leukemia. Value Health. 2015 Nov;18(7):A460.

NCPE. Cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with chronic lymphocytic leukaemia who have received _1 prior therapy, or as a first-line treatment in the presence of del(17p) or TP53 mutation in patients not suitable for chemoimmunotherapy. October 2015.

Rituximab for the first-line treatment of chronic lymphocytic leukaemia NICE technology appraisal guidance [TA174] Published date: 22 July 2009.

Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. NICE technology appraisal guidance [TA193] Published date: 28 July 2010

Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. NICE technology appraisal guidance [ta202] Published date: 27 October 2010

Idelalisib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance [TA359] Published date: 28 October 2015

DOI: http://dx.doi.org/10.14748/.v2i1.1886